Qutenza Kit
Product Images NDC 72512-930

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Qutenza (NDC 72512-930). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Averitas Pharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 6

A line graph comparing the proportion of patients against the percent reduction from baseline for two treatments: Qutenza and placebo. The graph shows two lines, one solid blue representing Qutenza and one dashed red representing placebo, with the proportion of patients decreasing as percent reduction increases.*

FDA Label Image

Figure 7

A line graph comparing the proportion of patients over a 12-week period between Qutenza (capsaicin) and placebo groups. The x-axis represents weeks, and the y-axis represents the proportion of patients. The Qutenza group is represented with a blue line and placebo with a red dashed line. An annotation notes that the same patients may not have responded at each time point.*

FDA Label Image

Image 001

An instructional illustration showing a gloved hand holding a pen or marker and drawing a dotted line around the side and top of a human foot, likely indicating an area boundary for treatment or application.*

FDA Label Image

Image 002

Illustration showing a hand applying a patch to the top of a foot near the toes. The image is likely instructional, demonstrating how to place a patch on the foot area.*

FDA Label Image

Image 003

An instructional illustration showing a person wearing gloves applying a patch to the bottom of a foot, indicating the proper placement technique for topical administration.*

FDA Label Image

Image 004

An instructional illustration showing hands wrapping or applying a bandage or tape around an ankle or foot. The focus is on the technique for securing the bandage around the joint area.*

FDA Label Image

Image 005

An instructional illustration showing a gloved hand applying a topical treatment with a swab or applicator to a marked area on the bottom of a foot. The diagram depicts the process of administering the medication, likely related to the Qutenza capsaicin kit.*

FDA Label Image

Figure 2.3-1 (Image 01)

An instructional illustration showing a person drawing a dashed circular mark on the lower abdomen, presumably indicating an application site. The figure includes part of the torso with a belt and hand holding a writing instrument positioned on the skin.*

FDA Label Image

Figure 2.3-2 (Image 02)

An instructional illustration shows a person applying a rectangular patch to the lower abdominal area, demonstrating the proper placement for using the Qutenza kit. The image focuses on hand placement and patch positioning on the skin.*

FDA Label Image

Figure 2.3-3 (Image 03)

An instructional illustration shows a hand applying a patch to the lower back or abdomen area of a person. The image is likely related to the application instructions for Qutenza (capsaicin) kit by Averitas Pharma Inc.*

FDA Label Image

Figure 2.3-4 (Image 04)

An instructional illustration showing a person wearing gloves applying the Qutenza kit patch to the lower torso or abdomen area. The image depicts hand positioning and placement guidance for the capsaicin topical treatment patch kit.*

FDA Label Image

Figure 2.3-5 (Image 05)

An illustration showing a person applying a treatment patch to the lower abdomen area. The person's torso is partially visible, with one hand holding the patch and positioning it on the skin near the waistline, demonstrating the application method.*

FDA Label Image

Structural Formula Of Capsaicin (Image 06)

Chemical structure diagram of capsaicin, the active ingredient in Qutenza, showing the molecular arrangement including a methoxyphenol group connected to an amide linkage and a hydrophobic alkyl chain.*

FDA Label Image

Figure 2 (Image 07)

A line graph comparing the proportion of patients versus percent improvement from baseline for Qutenza and a low-dose control. The graph shows two descending curves, with Qutenza consistently above the low-dose control, indicating a higher proportion of patients achieving improvement.*

FDA Label Image

Figure 3 (Image 08)

A line graph comparing the proportion of patients responding over 12 weeks to Qutenza versus a low-dose control. The x-axis represents weeks, and the y-axis shows the proportion of patients. The graph shows Qutenza maintaining a higher response proportion than the control throughout the period.*

FDA Label Image

Figure 4 (Image 09)

A line graph comparing the proportion of patients by percent improvement from baseline for Qutenza versus a low-dose control. The x-axis represents percent improvement from baseline (0 to 100), and the y-axis shows the proportion of patients (0 to 100). Qutenza is represented with a solid line, and the low-dose control with a dashed line.*

FDA Label Image

Figure 5 (Image 10)

A line chart comparing the proportion of patients responding over 12 weeks between Qutenza and a low-dose control. The vertical axis shows the proportion of patients from 0% to 100%, and the horizontal axis shows weeks from 0 to 12. The Qutenza group consistently shows a higher response proportion than the low-dose control group throughout the study period.*

FDA Label Image

Averitas Pharma Logo (Image 11)

FDA Label Image

Small Image 12

Packaging label for Qutenza (capsaicin) 8% topical system kit by Averitas Pharma Inc. The label indicates a single-use topical system containing 179 mg capsaicin, along with a single-use 50 g tube of cleansing gel. The design includes instructions for healthcare professional use and handling precautions.*

FDA Label Image

Small Image 13

The packaging label for Qutenza (capsaicin) 8% topical system kit manufactured by Averitas Pharma Inc. The label displays the product name, active ingredient, and strength prominently. It also includes instructions for healthcare professional use only, emphasizing the need to use nitrile gloves when handling. The label notes the kit contains two single-use topical systems and one tube of cleansing gel, with safety and handling information.*

FDA Label Image

Small Image 14

Packaging label for Qutenza 8% topical system featuring capsaicin. The label specifies it as a kit containing four single-use topical systems with 179 mg capsaicin each, including a three single-use 30 g tubes of cleansing gel. The labeler is Averitas Pharma Inc. The front panel prominently displays the brand name, strength, dosage form, and usage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.